Icesp - Instituto Do Câncer Do Estado de São Paulo Octavio Frias de Oliveira

São Paulo 01246-000

5 studies enrolling now · 10 studies all time

What they study most

Acute Myeloid Leukemia, Biliary Tract Cancer, Breast Cancer, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Colorectal Neoplasms, Gallbladder Cancer, Head and Neck Cancer, Leukemia, Non-small Cell Lung Cancer, Small Cell Lung Cancer

Studies at this site

• A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer — Recruiting now
• A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer — Recruiting now
• Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer — Recruiting now
• Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission — Recruiting now
• Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer — Recruiting now
• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML — Running, not enrolling
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) — Stopped early
• M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) — Stopped early
• Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC — Stopped early
• Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) — Completed